Suppr超能文献

病原体驱动的 CRISPR 筛选鉴定 TREX1 为流感病毒感染期间 DNA 自我感知的调节剂。

Pathogen-driven CRISPR screens identify TREX1 as a regulator of DNA self-sensing during influenza virus infection.

机构信息

Department of Medical Microbiology & Immunology, University of Wisconsin-Madison, Madison, WI 53706, USA.

Department of Pediatrics, University of Wisconsin-Madison, Madison, WI 53706, USA.

出版信息

Cell Host Microbe. 2023 Sep 13;31(9):1552-1567.e8. doi: 10.1016/j.chom.2023.08.001. Epub 2023 Aug 30.

Abstract

Host:pathogen interactions dictate the outcome of infection, yet the limitations of current approaches leave large regions of this interface unexplored. Here, we develop a novel fitness-based screen that queries factors important during the middle to late stages of infection. This is achieved by engineering influenza virus to direct the screen by programming dCas9 to modulate host gene expression. Our genome-wide screen for pro-viral factors identifies the cytoplasmic DNA exonuclease TREX1. TREX1 degrades cytoplasmic DNA to prevent inappropriate innate immune activation by self-DNA. We reveal that this same process aids influenza virus replication. Infection triggers release of mitochondrial DNA into the cytoplasm, activating antiviral signaling via cGAS and STING. TREX1 metabolizes the DNA, preventing its sensing. Collectively, these data show that self-DNA is deployed to amplify innate immunity, a process tempered by TREX1. Moreover, they demonstrate the power and generality of pathogen-driven fitness-based screens to pinpoint key host regulators of infection.

摘要

宿主-病原体相互作用决定了感染的结果,但目前的方法存在局限性,使得这一界面的很大一部分未被探索。在这里,我们开发了一种新颖的基于适应性的筛选方法,用于研究感染中后期重要的因素。通过工程化流感病毒,我们实现了这一目标,通过编程 dCas9 来调节宿主基因表达,从而引导筛选。我们进行了全基因组筛选以寻找促进病毒的因素,发现了细胞质 DNA 外切酶 TREX1。TREX1 降解细胞质 DNA,防止自身 DNA 引起不适当的先天免疫激活。我们揭示了这个相同的过程有助于流感病毒的复制。感染触发线粒体 DNA 释放到细胞质中,通过 cGAS 和 STING 激活抗病毒信号。TREX1 代谢 DNA,防止其被感知。总的来说,这些数据表明,自身 DNA 被用来放大先天免疫,而 TREX1 则对其进行了调节。此外,它们还展示了病原体驱动的适应性筛选在确定感染关键宿主调节剂方面的强大功能和通用性。

相似文献

9
TREX1 as a Novel Immunotherapeutic Target.TREX1 作为一种新型免疫治疗靶标。
Front Immunol. 2021 Apr 1;12:660184. doi: 10.3389/fimmu.2021.660184. eCollection 2021.

引用本文的文献

1
Advancements in CRISPR/Cas systems for disease treatment.用于疾病治疗的CRISPR/Cas系统的进展。
Acta Pharm Sin B. 2025 Jun;15(6):2818-2844. doi: 10.1016/j.apsb.2025.05.007. Epub 2025 May 17.

本文引用的文献

3
Retasking of canonical antiviral factors into proviral effectors.将经典抗病毒因子重新分配为病毒前体效应物。
Curr Opin Virol. 2022 Oct;56:101271. doi: 10.1016/j.coviro.2022.101271. Epub 2022 Oct 13.
9
The type I interferonopathies: 10 years on.Ⅰ型干扰素病:10 年进展。
Nat Rev Immunol. 2022 Aug;22(8):471-483. doi: 10.1038/s41577-021-00633-9. Epub 2021 Oct 20.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验